Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Merafloxacin [110013-21-3]

Research Use Only
AG-CR1-3756
AdipoGen Life Sciences
CAS Number110013-21-3
Product group Chemicals
Estimated Purity>98%
Molecular Weight379.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Merafloxacin
  • Delivery Days Customer
    10
  • CAS Number
    110013-21-3
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C19H23F2N3O3
  • Molecular Weight
    379.4
  • Scientific Description
    Chemical. CAS: 91188-00-0. Formula: C19H23F2N3O3. MW: 379.4. Merafloxacin is a fluoroquinolone broad-spectrum antibacterial compound. It is an inhibitor of bacterial DNA gyrase and Type II DNA topoisomerase. It demonstrated excellent activity against Gram-positive organisms and less potent activity against Gram-negative bacteria. Merafloxacin is a programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of SARS-CoV-2. Frameshift inhibition by merafloxacin is robust to mutations within the pseudoknot region and is similarly effective on -1 PRF of other betacoronaviruses and blocks SARS-CoV-2 replication in Vero E6 cells. The compound reduced viral levels in infected African green monkey VeroE6 cells in a concentration-dependent manner. Merafloxacin showed no cellular toxicity and resulted in a 3 to 4 orders of magnitude reduction of SARS-CoV-2 titer, with IC50 of 4.3 microMu. This compound provides a starting point for high-throughput screening for frameshifting inhibitors as a viable target for therapeutic intervention against SARS-CoV-2. - Merafloxacin is a fluoroquinolone broad-spectrum antibacterial compound. It is an inhibitor of bacterial DNA gyrase and Type II DNA topoisomerase. It demonstrated excellent activity against Gram-positive organisms and less potent activity against Gram-negative bacteria. Merafloxacin is a programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of SARS-CoV-2. Frameshift inhibition by merafloxacin is robust to mutations within the pseudoknot region and is similarly effective on -1 PRF of other betacoronaviruses and blocks SARS-CoV-2 replication in Vero E6 cells. The compound reduced viral levels in infected African green monkey VeroE6 cells in a concentration-dependent manner. Merafloxacin showed no cellular toxicity and resulted in a 3 to 4 orders of magnitude reduction of SARS-CoV-2 titer, with IC50 of 4.3 microMu. This compound provides a starting point for high-throughput screening for frameshifting inhibitors as a viable target for therapeutic intervention against SARS-CoV-2.
  • SMILES
    O=C1C2=CC(F)=C(N3CCC(CNCC)C3)C(F)=C2N(CC)C=C1C(O)=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200